Blog

ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to Evotec – Business Wire (press release)


Business Wire (press release)

ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to Evotec
Business Wire (press release)
“This license enables them to further expand their service offering in the CRISPR gene-editing space.” Evotec uses the CRISPR/Cas9 technology to drive its target identification platform as well as aid in the validation and unmasking of targets derived
Evotec Adds Licence From ERS Genomics To CRISPR Service Offering – Quick FactsNasdaq


Evotec Expands CRISPR-Based Technology Offering with Licence from ERS GenomicsDigital Journal

all 2 news articles »

2018-05-02 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.